Cite
Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairment.
MLA
Suda, Goki, et al. “Safety and Efficacy of Daclatasvir and Asunaprevir in Hepatitis C Virus-Infected Patients with Renal Impairment.” Hepatology Research, vol. 47, no. 11, Oct. 2017, pp. 1127–36. EBSCOhost, https://doi.org/10.1111/hepr.12851.
APA
Suda, G., Nagasaka, A., Yamamoto, Y., Furuya, K., Kumagai, K., Kudo, M., Terashita, K., Kobayashi, T., Tsunematsu, I., Yoshida, J., Meguro, T., Kimura, M., Ito, J., Umemura, M., Izumi, T., Tsunematsu, S., Sato, F., Tsukuda, Y., Nakai, M., & Sho, T. (2017). Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairment. Hepatology Research, 47(11), 1127–1136. https://doi.org/10.1111/hepr.12851
Chicago
Suda, Goki, Atsushi Nagasaka, Yoshiya Yamamoto, Ken Furuya, Kenichi Kumagai, Mineo Kudo, Katsumi Terashita, et al. 2017. “Safety and Efficacy of Daclatasvir and Asunaprevir in Hepatitis C Virus-Infected Patients with Renal Impairment.” Hepatology Research 47 (11): 1127–36. doi:10.1111/hepr.12851.